uniQure NVQURE -7.34%50 Pretax Margin % is -1,489.25% as of Mar. 2026. GuruFocus rates QURE with a GF Score™ of 50/100 and a GF Value™ of $5.99 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, uniQure NV ranks worse than 79.81% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. uniQure NV's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-53.05 Mil. uniQure NV's Revenue for the
three
months ended in Mar. 2026 was $3.56 Mil. Therefore, uniQure NV's pretax margin for the quarter that ended in Mar. 2026 was -1,489.25%.
The historical rank and industry rank for uniQure NV's Pretax Margin % or its related term are showing as below:
QURE'
s Pretax Margin % Range Over the Past 10 Years
Min: -1934.97 Med: -671.22 Max: 63.51
Current: -1123.34
QURE's Pretax Margin % is ranked worse than 79.81% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs QURE: -1123.34
uniQure NV (NAS:QURE) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
uniQure NV Pretax Margin % Related Terms
uniQure NV Pretax Margin % Historical Data
* Premium members only.
The historical data trend for uniQure NV's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QURE vs ALMS, ARQT, DYN: Pretax Margin % Comparison
For the Biotechnology subindustry, uniQure NV's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where uniQure NV's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (QURE) has a Pretax Margin % of -1,489.25% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #751 out of 941 companies in the Biotechnology industry, placing it in the top 79.8%.
Is uniQure NV's Pretax Margin % too high?
uniQure NV's current Pretax Margin % is -1,489.25%. Based on the distribution chart, uniQure NV ranks #751 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, uniQure NV has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Pretax Margin % compare to ALMS and ARQT?
According to the Biotechnology industry distribution chart, uniQure NV ranks #751 out of 941 companies for Pretax Margin %. This places uniQure NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on uniQure NV and its competitors. uniQure NV's current Pretax Margin % is -1,489.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (QURE) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.99, compared to a current price of $41.79 — trading 597.7% above its estimated fair value. The current Pretax Margin % is -1,489.25%. uniQure NV's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For uniQure NV (QURE), the current Pretax Margin % is -1,489.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (QURE) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $41.79 is trading 597.7% above its estimated GF Value™ of $5.99.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for QURE:
Pretax Margin %: -1,489.25%
GF Value™: $5.99 vs. price of $41.79 (597.7% above fair value)
No single metric tells the full story. See the QURE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
50GF Score
Get the complete analysis for QURE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QURE has been successfully added to your 
